Dr. Yuan Taize is a Chief Physician and holds a Ph.D. in Oncology, having graduated from the Sun Yat-sen University Cancer Center in 2008. With over 20 years of experience in radiation oncology, he previously served as the Deputy Director of the Department of Radiation Oncology at the Cancer Center of Guangzhou Medical University. He spent a year as a visiting scholar at the University of Iowa Holden Comprehensive Cancer Center and the Florida Proton Therapy Institute (2015–2016) and underwent specialized training in proton therapy at the Mayo Clinic Proton Beam Therapy Program (November 2019 – May 2020). Since joining Guangzhou Taihe Cancer Hospital in 2019, he has been deeply involved in the planning, design, and construction of the Radiation Oncology Center and has led his team in pioneering the clinical application of proton therapy in South China.
Prof. Taize Yuan, MD
| Speciality | Specializes in the treatment of malignancies such as head and neck cancers (including nasopharyngeal carcinoma), central nervous system malignancies, breast cancer, lung cancer, and colorectal cancer. |
| Affiliated Hospital : | Guangzhou Concord Cancer Center |
| Department : |
|
| Language : | Chinese, English |
Overview
Current Hospital Appointments
Department of Radiation Oncology
Academic & Professional Titles
- Council Member, 2nd Youth Council of the China Anti-Cancer Association (CACA)
- Standing Committee Member and Secretary-General, CACA Professional Committee on Tumor Microenvironment
- Chairperson, Professional Committee on Radiation Oncology, Guangdong Society of Organ Medicine and Technology
- Vice Chairperson, Oncology Medical Management Branch, Guangdong Medical Industry Association
- Vice Chairperson, Radiation Oncology Branch, Guangzhou Medical Association
- Standing Committee Member, Ion Radiotherapy Branch, China Association of Medical Equipment
- Committee Member, CACA Professional Committee on Tumor Particle Therapy
Clinical Expertise
- Specializes in precision radiotherapy for malignancies such as head and neck cancers (including nasopharyngeal carcinoma), central nervous system tumors, breast cancer, lung cancer, and colorectal cancer.
- Proficient in techniques including 3D conformal radiotherapy (3D-CRT), intensity-modulated radiotherapy (IMRT), stereotactic radiotherapy (SRT/SBRT), and image-guided radiotherapy (IGRT).
- Familiar with proton therapy technologies, workflows, clinical indications, and quality control procedures.
- Adheres to the “individualized treatment plan” philosophy in clinical practice, tailoring radiotherapy regimens to each patient’s specific condition to minimize side effects and improve quality of life.
Research & Publications
- Combination of Erlotinib and radiotherapy: Investigated the mechanism by which Erlotinib enhances the radiosensitivity of nasopharyngeal carcinoma cells, finding that it boosts the efficacy of radiotherapy by inducing G2/M cell cycle arrest (*Experimental & Therapeutic Medicine*, 2013).
- Reversal of multidrug resistance by microRNA-125b: Examined the mechanism by which miR-125b reverses cisplatin resistance in nasopharyngeal carcinoma cells by targeting Bcl-2 (*Molecular Medicine Reports*, 2017).
- Combination of Cetuximab and radiotherapy: Studied the radiosensitizing and apoptosis-inducing effects of Cetuximab on nasopharyngeal carcinoma cell lines (*Cancer Research on Prevention and Treatment*, 2011).
- IGFBP5 and carbon-ion radiotherapy sensitivity: Research on proteins associated with the efficacy of carbon-ion radiotherapy for prostate cancer revealed that high IGFBP5 expression may serve as a predictor of favorable treatment outcomes (Report at the 2019 PTCOG Annual Conference).
Honours & Awards
- “Accomplished Physician” (2026; hosted by Guangzhou Daily)
- “Representative Exemplary Physician” (2026; jointly selected by the Guangzhou Municipal Health Commission and the Guangzhou Federation of Trade Unions; 100 recipients citywide)
© 2026 China Medical Services. All rights reserved.